Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Co's existing focus is on the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus. Co.'s product candidate for the treatment of COVID-19 is bemnifosbuvir. For the treatment of chronic HCV infection, Co. is developing a combination of bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A inhibitor. Co. is developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. The AVIR YTD return is shown above.
The YTD Return on the AVIR YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AVIR YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AVIR YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|